AN2 Therapeutics (ANTX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

AN2 Therapeutics (ANTX) - corporate logo

AN2 Therapeutics, Inc. (ANTX) relies on outsourcing the production and testing of molecules to minimize capital expenditures. The business faces intense pressure from global pharmaceutical behemoths in the pulmonary therapy segment. The firm's environmental footprint is limited to bio-waste disposal. The current EV/EBITDA ratio stands at 0.00, which is detailed in the price action chart provided below.

AN2 Therapeutics - ANTX Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/16/2026)

Summary analytical data breakdowns for AN2 Bio (ANTX)

- current price and projected stock value:
- market capitalization details:
General company analysis:AN2 Therapeutics Inc ANTX
Product sample of AN2 Therapeutics Inc

The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before taxes and amortization, allowing for the determination of an asset's fair price regardless of its financing structure. By analyzing the trend of the base EV/EBITDA multiple, an investor assesses the capitalization stability of AN2 Therapeutics, Inc. (ANTX) against the backdrop of patent protection for its drugs, where delays in clinical trials may temporarily distort the company's fundamental value.